News
VNDA
4.480
-1.75%
-0.080
UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer of $7.75 per share in cash. Last week, Vanda rejected contract manufacturer's offer for 59%-70% premium to Wednesday's closing price. Vanda said it rejected the offer because it significantly undervalued company.
Reuters · 12h ago
Vanda Pharmaceuticals Shareholder ShareCap Says Company Board Must Explore Strategic Alternatives
Benzinga · 15h ago
SHAREHOLDER CAPITAL LLC : CALLS VANDA PHARMACEUTICALS' BOARD TO RECONSIDER FUTURE PAK'S OFFER
Reuters · 15h ago
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 1d ago
Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex
NASDAQ · 3d ago
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
The U.S. Supreme Court has reportedly declined to review Vanda Pharmaceuticals Inc’s attempt to revive patents for its sleep-disorder medication Hetlioz. Vanda had previously had its patents invalidated in a legal battle with generic drugmakers Teva Pharmaceutical Industries.
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 3d ago
BUZZ-Vanda Pharma falls as Supreme Court rejects case over sleep-drug patents
U.S. Supreme Court declines to hear bid by Vanda to revive patents for its sleep-disorder drug Hetlioz. Shares of drugmaker Vanda Pharmaceuticals down 6.1% to $4.80. Patents were previously declared invalid in dispute with generic drugmakers Teva.
Reuters · 3d ago
'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
U.S. Supreme Court declines to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz. The company's patents were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling.
Benzinga · 3d ago
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents. Vanda wanted to revive patents for its drug Hetlioz that were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling against the company.
Reuters · 3d ago
US Supreme Court reportedly declines to hear Vanda patent case
US Supreme Court reportedly declines to hear Vanda Pharmaceuticals' patent case. Vanda had appealed to the high court after a lower court ruled in 2022 that the company's patents for its sleep-wake disorder drug Hetlioz were invalid. The FDA declined to approve a label expansion for the drug last month.
Seeking Alpha · 3d ago
Weekly Report: what happened at VNDA last week (0415-0419)?
Weekly Report · 3d ago
Vanda under pressure from hedge fund to discuss Future Pak takeover offer
Hedge fund Butler Hall Capital is calling on Vanda Pharmaceuticals to discuss Future Pak's takeover bid for the company. The fund argues that Vanda is making a mistake by outright rejecting the offer. Vanda under pressure from hedge fund to discuss future Pak takeover offer.
Seeking Alpha · 6d ago
Deals of the day-Mergers and acquisitions
Investment fund Phoenix wins the privatization auction for a controlling stake in Brazilian power generator EMAE. French train manufacturer Alstom agrees to sell its North American rail signalling business to a German company. Lufthansa executives to attend a hearing to convince EU regulators to approve its bid for ITA Airways.
Reuters · 6d ago
Butler Hall Capital urges Vanda to engage in sales discussions
Butler Hall Capital urges Vanda Pharmaceuticals to engage in sales discussions with Future Pak. Vanda rejected a takeover proposal from Future Pak on April 17. The hedge fund manager said it is concerned Vanda's refusal to engage will impair its investment in the company. Shares of Vanda were up 4% in afternoon trade.
Reuters · 6d ago
BUTLER HALL CAPITAL LLC : VANDA PHARMACEUTICALS BOARD SHOULD FORM INDEPENDENT SPECIAL COMMITTEE TO ENGAGE WITH FUTURE PAK & RUN FULL SALES PROCESS
Reuters · 6d ago
BUTLER HALL CAPITAL LLC HAS ISSUED AN OPEN LETTER TO VNDA’S BOARD OF DIRECTORS URGING THE COMPANY TO RUN A FULL SALES PROCESS TO MAXIMIZE SHAREHOLDER VALUE
Reuters · 6d ago
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
NASDAQ · 04/18 13:44
Deals of the day-Mergers and acquisitions
U.S. FTC preparing to sue to block Coach parent Tapestry's $8.5 billion deal to buy Michael Kors owner Capri. Zuora, Aurubis, Vanda Pharmaceuticals, TAQA, Royal Mail in talks to be sold.
Reuters · 04/17 20:26
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
U.S. Stocks traded lower on Wednesday, with the Nasdaq Composite falling more than 100 points. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. European shares closed higher on Wednesday. In commodity news, oil traded down 3% to $82.78 and gold traded down 0.8%. U.s. Bancorp reported upbeat first-quarter FY24 earnings. Utilities shares rose by 1.5% on Wednesday after the company reported upbeat results.
Benzinga · 04/17 18:34
More
Webull provides a variety of real-time VNDA stock news. You can receive the latest news about Vanda Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).